{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:31:57Z","timestamp":1791657117843,"version":"4.3.4"},"reference-count":97,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Management of patients with severe bleeding disorders, particularly haemophilia A and B, and to a lesser extent, von Willebrand disease, has come on leaps and bounds over the past decade. Until recently, patients relied upon the administration of factor concentrates to prevent or treat bleeding episodes. Factor administration requires intravenous access and, in up to one\u2010third of patients, leads to the development of neutralising antibodies, or inhibitors, which are associated with more frequent bleeding episodes and higher morbidity. Novel non\u2010factor therapies may offer a solution to these unmet needs. In this review, we discuss the factor mimetics, particularly emicizumab, and the rebalancing agents, which inhibit antithrombin, tissue factor pathway inhibitor and activated protein C, and novel treatments to enhance von Willebrand factor levels. We review the available trial data, unanswered questions and challenges associated with these new treatment modalities. Finally, we provide practical management algorithms to aid the general haematologist when faced with a patient receiving emicizumab who requires surgery or may develop bleeding.<\/jats:p>","DOI":"10.1002\/jha2.442","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:04:48Z","timestamp":1651190688000},"page":"584-595","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Non\u2010factor therapies for bleeding disorders: A primer for the general haematologist"],"prefix":"10.1002","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-7333","authenticated-orcid":false,"given":"Dawn","family":"Swan","sequence":"first","affiliation":[{"name":"National University Ireland  Galway Republic of Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Haematology School of Pathology Faculty of Health Sciences University of the Witwatersrand and NHLS  Johannesburg South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[{"name":"Department of Haematology Manchester University Hospitals NHS Foundation Trust  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13616"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-05-0407"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573055"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30193-4"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-06-0444"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.02.030"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01435.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-479527"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/ort.1965.36.suppl-77.01"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.01036.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02383.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02539.x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966888"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07087.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1727"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00653.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.08.007"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464509"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12091"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12852"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13762"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_2_11_31_1","unstructured":"https:\/\/www.fda.gov\/drugs\/drug\u2010approvals\u2010and\u2010databases\/fda\u2010approves\u2010emicizumab\u2010kxwh\u2010hemophilia\u2010or\u2010without\u2010factor\u2010viii\u2010inhibitors. Accessed 5 Mar 2022."},{"key":"e_1_2_11_32_1","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemlibra. Accessed 5 Mar 2022."},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146009"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122817"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3847"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"key":"e_1_2_11_42_1","article-title":"Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia A or B without inhibitors (ATLAS\u2010A\/B)","volume":"138","author":"Srivastava A","year":"2021","journal-title":"ASH abstract"},{"key":"e_1_2_11_43_1","article-title":"Fitusiran population pharmacokinetic and pharmacodynamic (PopPK\/PD) modeling to support revised dose, dosing regimens & dose mitigation scheme","volume":"5","author":"Bhagunde P","year":"2021","journal-title":"ISTH abstract"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12897"},{"issue":"4","key":"e_1_2_11_45_1","first-page":"551","article-title":"Heterogeneity of plasma tissue factor pathway inhibitor","volume":"5","author":"Broze GJ","year":"1994","journal-title":"Blood Coagul Fibrinol"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14272"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12438"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114683"},{"key":"e_1_2_11_50_1","volume-title":"Anti\u2010TFPI antibody BAY 1093884: early termination of phase II dose escalation study due to thrombosis. Haemophilia","author":"Ferrante F"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12201"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04790.x"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1104.1104"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1183.bloodjournal8841183"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00551.x"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)39985-5"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100123200"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a134583"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718635"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16720-9"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504240103"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)70660-7"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-800326"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14359"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911298"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-401620"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14556"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14491"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S159297"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13903"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226"},{"key":"e_1_2_11_74_1","article-title":"Reducing antithrombin in plasma to levels observed in fitusiran\u2010treated patients does not interfere with coagulation assays","volume":"136","author":"Wang S, Kattula S","year":"2020","journal-title":"ASH abstract"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.284356"},{"key":"e_1_2_11_76_1","article-title":"Use of thromboelastography to monitor emicizumab in a patient with severe haemophilia A without inhibitor","volume":"4","author":"Tiscia GL, Cappucci F","year":"2020","journal-title":"ISTH abstract"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13495"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14010"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123654"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124108"},{"key":"e_1_2_11_81_1","article-title":"Surgical experience from four phase III studies (HAVEN 1\u20134) of emicizumab in persons with haemophilia A (PwHA) with or without","volume":"3","author":"Santagostino E","year":"2019","journal-title":"FVIII inhibitors. Res Pract Thromb Haemost."},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.89.89"},{"issue":"1","key":"e_1_2_11_83_1","first-page":"2366","article-title":"Perioperative management in patients with hemophilia receiving fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia","volume":"130","author":"Negrier C","year":"2017","journal-title":"Blood"},{"key":"e_1_2_11_84_1","article-title":"Perioperative management of patients with hemophilia receiving fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia","volume":"4","author":"Pasi KJ, Negrier C","year":"2020","journal-title":"ISTH abstract. Res Pract Thromb Haemost"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148571"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20422"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1127-6476"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003265"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245330500345710"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000656"},{"key":"e_1_2_11_91_1","article-title":"Prophylactic subcutaneous emicizumab\u2010kxwh in adults and children with symptomatic type 3 von Willebrand disease","volume":"5","author":"Pawar A","year":"2021","journal-title":"ISTH abstract. Res Pract Thromb Haemost"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12076"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.10.038"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006119"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1160\/th14-02-0148"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09167.x"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12195"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T23:08:16Z","timestamp":1692572896000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1002\/jha2.442"],"URL":"https:\/\/doi.org\/10.1002\/jha2.442","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"2022-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}